{"id":"omarigliptin","_chembl":null,"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=OMARIGLIPTIN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T05:52:43.011168+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T05:52:56.104187+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T05:52:49.100410+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=OMARIGLIPTIN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T05:52:49.395658+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Dipeptidyl peptidase IV inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T05:52:50.440090+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2105762/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T05:52:50.100168+00:00"}},"_dailymed":null,"aiSummary":"Omarigliptin is a marketed drug with a key composition patent expiring in 2028. Its primary strength lies in its extended patent protection, which helps maintain market exclusivity and revenue stability. The primary risk is the eventual patent expiry in 2028, which could lead to increased competition from generics.","_scrapedAt":"2026-03-27T23:35:17.669Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T05:52:56.104282+00:00","fieldsConflicting":0,"overallConfidence":0.95},"trialDetails":[{"nctId":"NCT06449235","phase":"PHASE4","title":"Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh","status":"NOT_YET_RECRUITING","sponsor":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","startDate":"2024-09","conditions":"Type2diabetes","enrollment":938},{"nctId":"NCT04365907","phase":"NA","title":"Omarigliptin in Four Healthy Egyptian Volunteers","status":"UNKNOWN","sponsor":"British University In Egypt","startDate":"2020-03-11","conditions":"Healthy Volunteers","enrollment":4},{"nctId":"NCT02906709","phase":"PHASE4","title":"Omarigliptin Add-on to Insulin in Japanese Participants With Type 2 Diabetes Mellitus (T2DM, MK-3102-039)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-10-17","conditions":"Type 2 Diabetes Mellitus","enrollment":184},{"nctId":"NCT01703221","phase":"PHASE3","title":"Omarigliptin (MK-3102) Clinical Trial - Placebo- and Sitagliptin-Controlled Monotherapy Study in Japanese Patients With Type 2 Diabetes Mellitus (MK-3102-020)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-24","conditions":"Type 2 Diabetes Mellitus","enrollment":414},{"nctId":"NCT01703208","phase":"PHASE3","title":"A Study to Assess Cardiovascular Outcomes Following Treatment With Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (MK-3102-018)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-05","conditions":"Type 2 Diabetes Mellitus","enrollment":4202},{"nctId":"NCT01704261","phase":"PHASE3","title":"Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-18","conditions":"Type 2 Diabetes Mellitus","enrollment":307},{"nctId":"NCT01841697","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-06-13","conditions":"Type 2 Diabetes","enrollment":642},{"nctId":"NCT01755156","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-01-11","conditions":"Type 2 Diabetes Mellitus","enrollment":402},{"nctId":"NCT01697592","phase":"PHASE3","title":"Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-24","conditions":"Type 2 Diabetes Mellitus","enrollment":585},{"nctId":"NCT01717313","phase":"PHASE3","title":"A Study to Assess the Safety and Efficacy of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control (MK-3102-011)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-12-05","conditions":"Type 2 Diabetes Mellitus","enrollment":329},{"nctId":"NCT01814748","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Omarigliptin (MK-3102) in ≥18 and <45 Year-Old Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK-3102-028)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-05-03","conditions":"Diabetes Mellitus","enrollment":203},{"nctId":"NCT01217073","phase":"PHASE2","title":"A Dose-Range Finding Study in Participants With Type 2 Diabetes (MK-3102-006)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-10-08","conditions":"Type 2 Diabetes Mellitus","enrollment":685},{"nctId":"NCT01863667","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus for Whom Metformin is Inappropriate (MK-3102-027)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-07-08","conditions":"Type 2 Diabetes Mellitus","enrollment":65},{"nctId":"NCT01088711","phase":"PHASE1","title":"Evaluation of Omarigliptin (MK-3102) in Obese Participants and in Participants With Type 2 Diabetes (MK-3102-004)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-03-11","conditions":"Type 2 Diabetes (T2D)","enrollment":32},{"nctId":"NCT01407276","phase":"PHASE1","title":"A Study of Omarigliptin (MK-3102) in Participants With Impaired Renal Function (MK-3102-009)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-08-08","conditions":"Chronic Renal Insufficiency, Type 2 Diabetes Mellitus","enrollment":49},{"nctId":"NCT01682759","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-09-10","conditions":"Type 2 Diabetes Mellitus","enrollment":751},{"nctId":"NCT01698775","phase":"PHASE3","title":"A Study of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-02","conditions":"Type 2 Diabetes Mellitus","enrollment":213},{"nctId":"NCT03362398","phase":"NA","title":"Omarigliptin & Trelagliptin in Twelve Healthy Egyptian Volunteers","status":"COMPLETED","sponsor":"British University In Egypt","startDate":"2017-11-20","conditions":"Diabetes Mellitus, Type 2","enrollment":12}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"AUTOIMMUNE DISORDER"},{"count":2,"reaction":"DIABETES MELLITUS"},{"count":2,"reaction":"DIARRHOEA"},{"count":2,"reaction":"FALL"},{"count":2,"reaction":"GLYCOSYLATED HAEMOGLOBIN INCREASED"},{"count":2,"reaction":"IRON DEFICIENCY ANAEMIA"},{"count":2,"reaction":"LOW DENSITY LIPOPROTEIN INCREASED"},{"count":2,"reaction":"MALAISE"},{"count":2,"reaction":"MYCOBACTERIAL INFECTION"},{"count":2,"reaction":"MYCOBACTERIUM AVIUM COMPLEX INFECTION"}],"crossReferences":{"chemblId":"CHEMBL2105762"},"_approvalHistory":[],"publicationCount":92,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"approved","brandName":"OMARIGLIPTIN","genericName":"OMARIGLIPTIN","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"2015","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T05:52:56.104282+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}